In the American Journal of Clinical Pathology, Health Care Attorney Examines the Use of Tissue in Clinical Trials
In the era of precision medicine there are competing demands placed on the use of tissue such as routine pathology diagnostics or biomarker studies to determine patient clinical trial eligibility or treatments.
In the American Journal of Clinical Pathology published on Oct. 15, health care partner Mark Barnes (Boston) and co-authors examined the barriers and strategic solutions to advance diagnostic tissue submission for clinical trials. Following a National Cancer Institute workshop, the authors propose recommendations to reduce institutional barriers and assist organizations in developing policies on diagnostic tissue block submission for clinical trials.